Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients

Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal